... we are in a situation of serious demographic decline, not only in Italy, but in other parts of the world like Japan or Spain. This…
In Conversation
The situation in Italy has changed; there is a new awareness of the importance of the life sciences/pharmaceutical industry
[In] the therapeutic areas where we are most active, the largest patient pool and therefore the highest unmet needs from a medical standpoint are in the…
We are the only CDMO represented in the SMI’s Health Systems Task Force ... This foregrounds our positioning as a strategic partner to pharma and a…
We believe that to concretely help patients, we need not only a traditional and pharmacological commitment but also a social and educational one
Egypt is a place where it takes longer to do business, there are hurdles because we have a huge administration and bureaucracy, but it is worth…
Even though we are a mid-sized company, and the competition is tough, we are working very hard to achieve success [in oncology]
Immuno-oncology has revolutionized cancer therapy, but despite the huge success there has been in the area, there are still many unmet patient needs
Our preclinical data and clinical experience with our pipelines have been highly promising, and we are eager to advance our clinical trials to later stages.
UCB has a firm commitment to innovation as evidenced by the fact that it invests 28% of its turnover in R&D.
We are the shining star in the Middle East, with a strategic location, fantastic connectivity, effective governance and regulations – we expect these qualities to attract…
[In the National Recovery and Resilience Plan] AGENAS is ... the point of connection between the Ministry of Health and the regions [and] EUR 15.63 billion…
